Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Theralase Technologies (TSXV:TLT) signed a clinical development agreement with Ferring Pharmaceuticals to evaluate a new ...
Sportschosun on MSN
Professor Kim Kwang-pyo's team at Kyung Hee University develops next-generation anti-cancer technolo...
A research team led by Professor Kim Kwang-pyo of Kyung Hee University's Department of Applied Chemistry has developed a next ...
How bladder cancer originates and progresses has been illuminated as never before. Researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early ...
Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback